Supportive care of the marrow transplant recipient: the Seattle Experience.

Abstract

It is now almost 2 decades after the first successful human marrow transplants from HLA-identical siblings for the treatment of life-threatening hematologic diseases. Results have improved, especially for patients transplanted earlier in the course of disease. However, major problems remain in supporting patients through the transplant. More effective and less toxic conditioning regimens are needed. Acceleration of hematopoietic and immunologic reconstitution by use of various cytokines holds promise for decreasing infectious morbidity and mortality. Improved regimens to control acute and chronic GVHD and prevent opportunistic infections will play a major role in the advancement of supportive care of the marrow transplant recipient.

• Authors: K M Sullivan, J Meyers, F B Petersen, R Bowden, G C Counts, M Banaji, M Schubert, J Clark, R A Clift, F R Appelbaum
• Journal: Haematology and blood transfusion (Haematol Blood Transfus) Vol. 33 Pg. 539-45 ( 1990) ISSN: 0171-7111 [Print] Germany
• PMID: 2182446 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Anti-Infective Agents
• Antibiotics, Antineoplastic
• Colony-Stimulating Factors

Topics

• Anti-Infective Agents (therapeutic use)
• Antibiotics, Antineoplastic (adverse effects)
• Blood Transfusion
• Bone Marrow Transplantation (adverse effects, immunology, nursing)
• Colony-Stimulating Factors (therapeutic use)
• Combined Modality Therapy
• Graft Survival
• Graft vs Host Disease
• Hematopoiesis
• Humans
• Immunosuppression Therapy (adverse effects)
• Infections (drug therapy, etiology)
• Whole-Body Irradiation (adverse effects)